- Home
- IRON vs FORTY Comparison
IRON vs FORTY Comparison
Compare IRON & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- FORTY
- Stock Information
- Founded
- IRON 2017
- FORTY 1985
- Country
- IRON United States
- FORTY Israel
- Employees
- IRON N/A
- FORTY N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- FORTY EDP Services
- Sector
- IRON Health Care
- FORTY Technology
- Exchange
- IRON Nasdaq
- FORTY Nasdaq
- Market Cap
- IRON 1.4B
- FORTY 1.3B
- IPO Year
- IRON N/A
- FORTY 1997
- Fundamental
- Price
- IRON $46.68
- FORTY $110.00
- Analyst Decision
- IRON Strong Buy
- FORTY
- Analyst Count
- IRON 9
- FORTY 0
- Target Price
- IRON $93.89
- FORTY N/A
- AVG Volume (30 Days)
- IRON 354.8K
- FORTY 356.0
- Earning Date
- IRON 05-07-2025
- FORTY 05-22-2025
- Dividend Yield
- IRON N/A
- FORTY 1.16%
- EPS Growth
- IRON N/A
- FORTY 25.14
- EPS
- IRON N/A
- FORTY 5.21
- Revenue
- IRON N/A
- FORTY $2,813,792,000.00
- Revenue This Year
- IRON N/A
- FORTY N/A
- Revenue Next Year
- IRON N/A
- FORTY N/A
- P/E Ratio
- IRON N/A
- FORTY $20.09
- Revenue Growth
- IRON N/A
- FORTY 5.92
- 52 Week Low
- IRON $30.82
- FORTY $69.07
- 52 Week High
- IRON $68.73
- FORTY $110.00
- Technical
- Relative Strength Index (RSI)
- IRON 49.90
- FORTY 74.48
- Support Level
- IRON $44.85
- FORTY $85.30
- Resistance Level
- IRON $47.36
- FORTY $100.00
- Average True Range (ATR)
- IRON 2.23
- FORTY 0.48
- MACD
- IRON -0.12
- FORTY 0.92
- Stochastic Oscillator
- IRON 37.58
- FORTY 100.00
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About FORTY Formula Systems (1985) Ltd.
Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources; Michpal; ZAP Group and Others. The majority of the company's revenue comes from Israel.